GLP-1 medications: separating real benefits from TikTok hype

What did @iamkamiam_ actually say?

The short version: she tried a cheap online GLP-1 source, hated it, switched to her primary care doctor, found it too expensive, and landed on Found as a more affordable middle ground. That is the whole arc of the video.

She says Found offers "the same exact medication" she was getting from her doctor, accepts insurance, and has more affordable options. Those are the three factual claims worth examining. The rest is personal narrative, which is fine, but the "same exact medication" line is where things get clinically complicated and where telehealth platforms have to be careful.

She also describes her first source as "mad sketchy" without naming it. That vague warning is actually doing real work for consumer safety, even if it is not rigorous health journalism.

Does the science back this up?

The cost and access problems she describes are real and well-documented. The "same exact medication" claim needs significant qualification depending on what she was actually prescribed.

GLP-1 receptor agonists like semaglutide and tirzepatide are expensive. A 2023 analysis by Dusetzina et al. in JAMA found that list prices for semaglutide exceeded $900 per month, placing them out of reach for most uninsured patients. Insurance coverage is inconsistent: a 2023 KFF report found that fewer than half of large employer plans covered Wegovy for weight loss, though coverage for diabetes indications is broader.

Telehealth platforms have genuinely expanded access to these medications. A 2022 study by Bhatia et al. in Obesity found that telehealth delivery of obesity treatment was non-inferior to in-person care for weight outcomes over 12 months. So the access argument has legitimate backing.

The "same exact medication" framing is the problem. If Found is prescribing FDA-approved brand-name semaglutide or tirzepatide, that is one thing. If it is compounded semaglutide from a 503A or 503B pharmacy, those are not the same product, and the FDA has been explicit about that distinction since 2024.

What did they get wrong (or right)?

She got the core consumer experience right. The unregulated online peptide market is genuinely dangerous, and her instinct to leave a sketchy provider was correct.

Where she oversimplifies is the "same exact medication" claim. Compounded semaglutide is not the same as Ozempic or Wegovy. The FDA removed semaglutide from its drug shortage list in 2024, which means compounding pharmacies are now legally prohibited from producing most compounded versions. Tirzepatide remains more complicated. Calling compounded and brand-name versions equivalent is not just legally problematic, it is scientifically inaccurate. Inactive ingredients differ. Manufacturing standards differ. Bioavailability data on compounded versions is limited.

She does not make any disease-cure claims, does not mention doses, and does not recommend stacking other compounds. Those are real points in her favor. The ad disclosure is present in the hashtags, which meets minimum FTC requirements, though burying it in hashtags is a known gray area that the FTC's 2023 updated endorsement guides specifically called out.

What should you actually know?

If you are considering a telehealth platform for GLP-1 medications, the access and cost benefits are real. But "affordable" often means compounded, and compounded is not the same as brand-name, legally or clinically.

Ask any platform directly: are you prescribing FDA-approved brand-name medication, or compounded semaglutide or tirzepatide from a compounding pharmacy? That answer matters. The FDA's 2024 guidance made clear that compounded semaglutide products are not FDA-approved and carry no guarantee of safety or efficacy equivalent to approved drugs (FDA, 2024).

Insurance coverage claims also need scrutiny. Many plans cover GLP-1s for type 2 diabetes but not for weight management. Some telehealth platforms quote insurance acceptance rates that apply only to specific indications. Verify your own plan before assuming coverage.

• The "sketchy online" category she describes likely refers to unregulated peptide vendors or gray-market compounding pharmacies, which operate outside FDA oversight entirely.
• Found is a legitimate telehealth platform with licensed clinicians. That does not mean every prescription they write is for brand-name medication.
• Your best protection is asking specific questions about what you are being prescribed before you fill anything.